Amrit Ray - 14 May 2026 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Reporting relationship: Director
Issuer ticker: RARE
Reported as of: 14 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 May 2026, 18:39:51 UTC
Prior SEC filing: 12 Jun 2025
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Karah Parschauer, attorney-in-fact

Key filing fact

Amrit Ray filed Form 4 for Ultragenyx Pharmaceutical Inc. (RARE) on 18 May 2026.

Key facts

This page summarizes Amrit Ray's Form 4 filing for Ultragenyx Pharmaceutical Inc. (RARE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 May 2026, 18:39.

Change

Previous filing in this sequence was filed on 12 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001924797 Primary reporting owner

Ray Amrit

Relationship: Director
Address: C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO
Signature: /s/ Karah Parschauer, attorney-in-fact
Signature date: 18 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RARE transaction

Common Stock

Award

Transaction value
Shares: +7,751
Change %: +33%
Price: $0.000000^*
Shares after: 31,116
Date: 14 May 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RARE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +14,058
Change %
Price: $0.000000^*
Shares after: 14,058
Date: 14 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,058
Exercise price: $25.80
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

Footnote F2

The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.